The announcement barely registered. When Israeli biotech Finally Foods disclosed it had raised a total of $2.6 million in pre-seed funding as of April 2026, the milestone landed with a muted thud in an alternative protein sector that had watched investment crater. The numbers tell part of the story—capital inflows to alt-protein ventures had fallen to roughly $881 million in 2025, a steep decline from the heady days when fermentation startups commanded nine-figure rounds and breathless headlines.
Yet something about Finally Foods' approach merits a closer look. The company isn't building steel bioreactors or staffing up fermentation facilities. Instead, it's wagering that plants themselves—potatoes, specifically—offer a cheaper, potentially faster path to producing the casein proteins that give cheese its signature melt and stretch. It's molecular farming, not precision fermentation, and a small but growing cohort of startups is making similar bets.
Whether they're right is an open question, one that hinges on biology, economics, and regulatory pathways still taking shape.
The Pitch: Let Photosynthesis Do the Work
The logic sounds almost too straightforward. Rather than constructing multimillion-dollar fermentation facilities—the capex gauntlet that has squeezed more than a few competitors—molecular farming companies insert genes directly into crops. Potatoes, soybeans, safflower, rice. Then they plant seeds and let photosynthesis handle the heavy lifting.
Finally Foods, co-founded by CEO Dafna Gabbay and CTO Dr. Basia J. Vinocur, is engineering potatoes to express all four casein subunits—αS1, αS2, β, κ—within a single plant cell. The target is the micellar structure, that complex assembly of proteins that makes cheese behave like cheese. According to the company, four potatoes could theoretically yield casein equivalent to one liter of milk. Commercial validation, of course, remains somewhere down the road.
The appeal is partly financial, partly logistical. Precision fermentation for dairy proteins has seen production costs tumble—from over $100 per kilogram in the early days to somewhere in the $20–45 range more recently, at least according to vendor estimates and market research. Even so, building out fermentation capacity at food-grade scale demands substantial infrastructure. Molecular farming proponents argue they can sidestep some of that burden by leveraging existing agricultural supply chains and extraction methods already used for potato starch and protein.
Whether the yield and purity actually pencil out at commercial tonnage? That's the multimillion-dollar question investors are underwriting.
Finally Foods entered field trials in southern Israel, running successive rounds to test lines expressing different casein combinations. The progression reflects the iterative, sometimes maddeningly slow reality of plant biotech—each growing season a gated milestone, each harvest a data point. The company holds an exclusive license to Evogene's GeneRator AI platform, a computational biology tool meant to compress those R&D cycles by designing genetic constructs and predicting outcomes before seeds ever hit soil.
A Crowded Field, Divergent Strategies
Finally Foods has company—quite a bit of it.
At least 17 primary molecular farming startups are targeting food ingredients, with another 17 diversified players pursuing adjacent applications, according to data compiled by the Good Food Institute as of June 2025. Cumulative private investment in plant molecular farming tallied roughly $196 million over several years—a fraction of the broader alternative protein landscape, but growing as technical proof points accumulate.
Alpine Bio, formerly known as Nobell Foods, is engineering soybeans to produce casein and has since expanded its remit to up to 15 different proteins. Cheeses will eventually launch under the Nobell brand. The company secured its tenth U.S. patent in late 2024, part of an IP land grab playing out across the sector.
NewMoo, another Israeli startup, is producing what it describes as a "liquid casein base" in soy, positioning the approach as more cost-effective by skipping powder isolation and purification steps altogether. Miruku, based in New Zealand, received field-trial licenses from Australia's Office of the Gene Technology Regulator to test dairy proteins in canola and safflower through the end of the decade. Japan's Kinish raised roughly $800,000 to develop rice-based casein.
The choice of host crop varies, and each carries trade-offs. Potatoes bring established protein extraction infrastructure. Soybeans carry high protein loads and well-worn value chains. Oilseeds like safflower and canola fit neatly into existing crush and refining operations. None is clearly superior; each founder is making a calculated bet on yield, agronomic footprint, and downstream processing complexity.
Moolec Science, a Luxembourg-based company that trades on Nasdaq, has hedged its bets with a portfolio approach: safflower for chymosin (a cheese-making enzyme) and gamma-linolenic acid, soybeans for porcine proteins, and more recently—announced in April 2026—pea seeds for bovine myoglobin. The diversification acknowledges a reality the pharmaceutical industry learned long ago—no single production platform dominates every application.
Regulatory Mazes and the Allergen Caveat
Getting from field trial to grocery shelf means threading a regulatory framework still finding its footing.
In the United States, APHIS—the Animal and Plant Health Inspection Service—oversees the introduction and movement of genetically engineered plants under 7 CFR Part 340. The agency has reinstated notifications and finalized additional exemptions in recent years, though a federal court vacated part of the SECURE rule, creating interim uncertainty. Developers now rely on permits, notifications, and case-by-case engagement while regulators regroup.
For the protein itself, FDA jurisdiction takes over. And here's where things get tricky for consumers hoping these products might offer allergen-free alternatives.
They won't.
Under the Food Allergen Labeling and Consumer Protection Act, casein—regardless of where or how it's produced—must be labeled as containing milk. FDA guidance is unambiguous on this point. Any cheese or protein powder derived from plant-grown casein will carry a milk allergen disclosure. The regulatory reality narrows the addressable market to consumers seeking animal-free production for environmental or ethical reasons, not allergen avoidance.
Finally Foods has indicated plans to begin USDA cultivation and FDA ingredient filings, with parallel approvals in Israel to fulfill its agreement with Central Bottling Company, the Israeli beverage conglomerate that led the company's $1.2 million round in September 2025 and serves as a commercial offtake partner. CEO Gabbay has publicly projected first pilot products—extracted powders for B2B evaluation, not yet retail cheese—within the next few years.
Then there's stewardship, which may prove thornier than the science itself.
Introducing milk proteins into staple crops like potatoes or soybeans raises the specter of adventitious presence—unintended mixing into the broader food supply. Identity-preserved production systems, already deployed for specialty grains and oilseeds, will be essential. Industry groups have begun adapting Excellence Through Stewardship frameworks to address the unique risks of what some call "special traits," but protocols remain works in progress. One errant potato in the wrong processing stream, and you've got an allergen contamination problem.
Sizing the Prize
The target market is sizable, if diffuse.
The casein derivatives market has been valued in the low billions, with micellar casein—the functional form Finally Foods and others are chasing—representing a meaningful slice. The global cheese market, depending on methodology, sits somewhere between $174 billion and $208 billion. U.S. dairy exports have hit records recently, with cheese shipments showing double-digit growth, underscoring resilient demand for high-protein dairy ingredients.
Precision-fermented dairy proteins, meanwhile, are scaling from a small base, with market projections showing rapid growth over the next decade. If molecular farming can match or undercut those economics while sidestepping some of the fermentation infrastructure burden, it carves out competitive space.
But that "if" is doing a lot of work. Expression levels, extraction efficiency, and micellar assembly in planta all need to prove out at tonnage that matters.
Broader agri-foodtech investment has softened, with capital shifting toward deeptech and away from some of the more speculative food innovation plays. Alternative proteins captured just a fraction of total ag investment in recent periods, with fermentation claiming the lion's share of that. Molecular farming's fundraising activity sits well below the thresholds that defined the frothier years.
Perhaps that's the point. Founders are building with less, betting on biology's leverage rather than brute-force capitalization.
The Clock Is Ticking
The next 18 to 24 months will likely separate science projects from scalable businesses—or at least begin to.
Regulatory clarity will set the pace. APHIS's amended guidance, FDA's treatment of novel ingredients, the resolution of legal challenges to existing frameworks. Stewardship and identity preservation will either become routine hygiene factors or bottlenecks, depending on how rigorously the industry and regulators enforce segregation.
Finally Foods has indicated plans to raise a seed round that would fund expanded field trials, deeper engagement with Central Bottling Company, and the beginnings of a U.S. regulatory dossier. The company's reliance on Evogene's AI platform to compress iteration cycles amounts to a bet that computational biology can offset the biological clock of growing seasons. Whether that advantage is real or marketing gloss will become clearer as third-party data on expression levels and extraction yields emerges—or doesn't.
For investors, the molecular farming thesis hinges on a few interdependent propositions. Can plants express complex multi-subunit proteins at commercial yields? Will extraction and purification costs stay competitive with fermentation? Do regulatory pathways open without prohibitive delays? Does stewardship impose crippling overhead?
None of those is guaranteed. But if the pieces align, the sector may offer a lower-capex wedge into a dairy protein market measured in billions, with climate and land-use narratives that resonate beyond the niche.
The question is whether potatoes—and soybeans, and safflower, and rice—can deliver on the promise before the capital runs out. Or before the next growing season reveals what the last one obscured.
